CD19 and diffuse large B-cell lymphoma: To date, two autologous CAR-T cell therapies directed against CD19 have been approved for use in the treatment of B-cell lymphomas including relapsed or refractory acute lymphoblastic lymphoma (ALL) and diffuse large cell B-cell lymphoma (DLBCL) [2].